Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Doximity, Inc.
DOCS
NYSE·Healthcare·Medical - Healthcare Information Services·Mkt cap $4.0B
$21.86
▲ +1.25%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$17.15 - $76.51
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 63.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Largest physician network with 80%+ U.S. doctor penetration creating powerful network effects
- Direct access to high-value pharmaceutical and healthcare system customers willing to pay premium rates
- HIPAA-compliant, purpose-built platform with high switching costs and deep physician engagement
- Recurring subscription-based revenue model with high gross margins and predictable cash flows
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expansion of pharmaceutical advertising and sponsored content monetization
Value
Undervalued - trading well below Healthcare IT & Services peers
Momentum
Weak
-5.2% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying DOCS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 6, 2026
MAY 13, 2026
Reported EPS of $0.26 vs $0.28 consensus (-7.1% surprise). Revenue of $145.4M vs $144.0M expected (+0.9%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-7.1%
Next: Aug 6, 2026
Revenue trend · last 8Q
—
—
—
—
+17%
+15%
+23%
+10%
Q4 24
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
$118.1M
$126.7M
$136.8M
$168.6M
$138.3M
$145.9M
$168.5M
$185.1M
Margins · last 8Q
Gross
89.9%
Operating
38.9%
Profit
33.3%
Wall Street consensus
20 analysts · 35% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
35%
Hold
60%
Sell
5%
Median Price Target
$24.00
▲ +9.8% vs $21.86
Latest: Citi · Jun 29, 2026
12 analysts covering